Navigation Links
Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
Date:7/11/2012

SAN DIEGO, July 11, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that the Company was recently named as one of the San Diego Business Journal's, 2012 Best Places to Work in San Diego.  The county-wide survey and awards program is designed to identify, recognize and honor the best places of employment in San Diego, benefiting the county's economy, workforce and businesses.

"We are honored to have been selected as one of the 2012 Best Places to Work in San Diego," said James Levine, President and Chief Executive Officer at Verenium. "Our employees are key to our success and we are committed to creating an environment that attracts top industrial biotechnology talent as we grow our business."

The rankings of the Best Places to Work in San Diego will be unveiled at an awards ceremony and in a San Diego Business Journal special publication in mid August.  For more information on the Best Places to Work in San Diego program, visit www.BestPlacesToWorkSD.com.

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's technology, products and product candidates, lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates, dependence on patents and proprietary rights, protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody
Manager, Corporate Communications
858-431-8581
sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation To Announce First Quarter 2012 Financial Results
2. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium to Present at Baird Clean Technology Conference
5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
6. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
7. TREVENTIS Corporation Scientific Founder, Donald Weaver, MD, Named Sobey Chair in Alzheimers Disease Research, His Third Endowed Chair
8. China Cord Blood Corporation Continues Share Repurchase Program
9. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor
10. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
11. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at FireflySci, ... What sets them apart from other cuvette manufacturers is their supercharged customer service ... On top of this steady flow of inside information, they have recently revamped ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered organ ... and bronchus, today announced that CEO Jim ... CEO & Investor Conference on Tuesday, February ... New York City . HART,s presentation ...
(Date:2/3/2016)... ... 2016 , ... Resilinc released online today its ... 750 unique supply chain notifications and alerts generated by its EventWatch ® ... management practitioners subscribe to the EventWatch service to receive early warnings and analysis ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
Breaking Biology News(10 mins):